Showing 221-230 of 1090 results for "".
That’s a Wrap: ICSC 2025
https://modernod.com/topics/contact-lenses/thats-a-wrap-icsc-2025/39020/Highlights from the annual scleral lens meeting.Understanding Antibody-Drug Conjugates (ADCs)
https://modernod.com/specialty/optometry/understanding-antibody-drug-conjugates-adcs-2421/32346/Learn how ocular metastatic lesions can vary depending on the type of cancer and about ocular adverse effects of certain cancer medications.GA Cases in the Primary Eye Care Clinic: Can You Spot the Three Signs?
https://modernod.com/series/2419-ga/ga-cases-primary-eye-care-clinic-can-you-spot-the-three-signs/30027/Drs. Modi and Mammo highlight the criteria for defining atrophy based on OCT findings and present a case.The Near Future in Managing Dry Eye Disease
https://modernod.com/mod-issues/marchapril-2025-supplement/the-near-future-in-managing-dry-eye-disease/38940/A closer look at the biggest challenges in treating DED and what’s in the pipeline.Opposition Mounts Against Tariffs on Optical Products
https://modernod.com/articles/significant-findings/opposition-mounts-against-tariffs-on-optical-products/39901/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all cuAvaGen™, The Genetic Eye Test in Modern Practice
https://modernod.com/mod-issues/supplements-inserts/avagen-the-genetic-eye-test-in-modern-practice-1/38330/How can the addition of genetic data guide treatment decisions?Premium Surgical Comanagement: Introducing iStent inject W
https://modernod.com/mod-issues/supplements-inserts/premium-surgical-comanagement-introducing-istent-inject-w/38285/Technology offers the opportunity to treat glaucoma during cataract surgery.Antibody Drug Conjugates: Pretreatment Assessment and Ocular Toxicity Awareness
https://modernod.com/specialty/optometry/adcs-pretreatment-assessment-2421/32361/Learn more about pretreatment assessment and ocular toxicity management for patients treated with antibody drug conjugates.GA Cases in the Primary Eye Care Clinic: Referring Earlier
https://modernod.com/series/2419-ga/ga-cases-primary-eye-care-clinic-referring-earlier/30026/Drs. Modi and Pecen present cases and discuss what OCT biomarkers to look for when determining when to refer a patient for GA treatment.Achieving Durable Outcomes in Treatment-Naïve nAMD
https://modernod.com/specialty/retina/Achieving-Durable-Outcomes-in-treatment-naive-nAMD-2506/33189/Drs. Garg and Wykoff discuss a treatment-naïve patient with neovascular age-related macular degeneration and the impact of second-generation agents.